Articles

Sometimes a report comes out that just makes no sense. Recently the US Preventive Services Task Force (USPSTF) has issued a statement that limited evidence exists to recommend screening adults for type 2 diabetes. Limited evidence? How ridiculous is this? Give us your comment!

High Protein Diets- Do They Work?? Kelli Culler, Doctor of Pharmacy Candidate, University of Florida, has found some interesting information after researching a little seen article. Click here to learn what she found out.

The once a day drug, liraglutide, is a laboratory-made version of glucagon-like peptide-1 (GLP-1), a hormone produced by the body. Several members of the GLP-1 family are in clinical trials, and one (Byetta) already has been approved by the U.S. Food and Drug Administration.

Denmark’s Novo Nordisk, the world’s biggest maker of insulin, on Friday said it expected to start a Phase III trial for its drug candidate liraglutide in obesity before the end of this year.

Treatment showed a 2.9% drop in A1c and a 27.5lb weight loss in 30 weeks.

Takeda Pharmaceutical Co said last Wednesday it had applied for approval to market in the United States the DPP-4 inhibitor Alogliptin and the Actos diabetes drugs in a single tablet for the treatment of type 2 diabetes.

First in class drug stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism.

Hyperglycemia is a risk factor for incident hypertension in type 1 diabetes, and intensive insulin therapy reduces the long-term risk for the development of hypertension.

New research suggests improved patient education can play a key role in halting the escalation of diabetes and reduce both the financial and personal impact of diabetes in our society.

Pre-mixed insulin analogues, a modified form of conventional pre-mixed human insulin, are more effective than long-acting analogues for controlling high blood sugar levels after meals in patients with type 2 diabetes, according to a new report.